EyePoint (EYPT) Short-term Investments (2011 - 2026)
EyePoint (EYPT) posted Short-term Investments of $144.8 million for Q1 2026, down 29.1% sequentially from $204.3 million in Q4 2025, and down 37.85% YoY from $233.0 million in Q1 2025.
Analysis
EyePoint (EYPT) Short-term Investments (2011 - 2026) Analysis & Trends
EyePoint has reported Short-term Investments for 13 years, with the latest figure at $144.8 million in Q1 2026.
- Quarterly Short-term Investments fell 37.85% year-over-year to $144.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $144.8 million (down 37.85% YoY) and the FY2025 annual result came in at $204.3 million, down 24.68% from the prior year.
- Short-term Investments eased to $144.8 million in Q1 2026 per EYPT's latest filing, from $204.3 million in the prior quarter.
- Over five years, Short-term Investments peaked at $271.2 million in Q4 2024 and troughed at $2.9 million in Q2 2023.
- A 5-year average of $114.2 million and a median of $89.2 million in 2022 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2023 and 2024: Short-term Investments slumped 96.74% in 2023, then soared 6433.76% in 2024.
- Over 5 years, Short-term Investments stood at $48.9 million in 2022, then gained by 1.76% to $49.8 million in 2023, then surged by 444.74% to $271.2 million in 2024, then retreated by 24.68% to $204.3 million in 2025, then retreated by 29.1% to $144.8 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $144.8 million, $204.3 million, and $129.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 70.01 Mn |
| Mar 31, 2026 | 144.83 Mn |
| Dec 31, 2025 | 204.27 Mn |
| Sep 30, 2025 | 129.45 Mn |
| Jun 30, 2025 | 184.59 Mn |
| Mar 31, 2025 | 233.04 Mn |
| Dec 31, 2024 | 271.21 Mn |
| Sep 30, 2024 | 173.96 Mn |
| Jun 30, 2024 | 189.48 Mn |
| Mar 31, 2024 | 28.34 Mn |
| Dec 31, 2023 | 49.79 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 2.94 Mn |
| Mar 31, 2023 | 16.72 Mn |
| Dec 31, 2022 | 48.93 Mn |
| Sep 30, 2022 | 81.90 Mn |
| Jun 30, 2022 | 89.03 Mn |
| Mar 31, 2022 | 89.24 Mn |
| Dec 31, 2021 | 33.00 Mn |
| Mar 31, 2017 | 2.50 Mn |